Images List Premium Download Classic

Neurological

Neurological-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Neural specific s100-beta for biomarker assays and devices for detection of a neurological condition
Banyan Biomarkers, Inc.
June 22, 2017 - N°20170176460

An in vitro diagnostic (ivd) device is used to detect the presence of and/or severity of neural injuries or neuronal disorders in a subject. The ivd device relies on an immunoassay which identifies biomarkers that are diagnostic of neural injury and/or neuronal disorders in a biological sample, such as whole blood, plasma, serum, and/or cerebrospinal fluid (csf). ...
NEW Processes for the preparation of oxytocin analogues
Hoffmann-la Roche Inc.
June 22, 2017 - N°20170174725

Provided herein is a process for the preparation of oxytocin receptor agonists that have the potential to be used for the treatment of neurological disorders.
NEW 2,5-dialkyl-4-h/halo/ether-phenol compounds
Hoffmann-la Roche Inc.
June 22, 2017 - N°20170174600

Wherein r2, r4, & r5, are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating neurological conditions.
NEW Neurological Patent Pack
Download 364+ patent application PDFs
Neurological Patent Applications
Download 364+ Neurological-related PDFs
For professional research & prior art discovery
inventor
  • 364+ full patent PDF documents of Neurological-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Har-nds-derived stem cells, method for separating same, and use thereof
Eutilex Co., Ltd
June 22, 2017 - N°20170173077

The present invention relates to hyaluronic acid-rich node and duct system (har-nds)-derived stem cells, a method for separating the same, and a use thereof and, more specifically, to node and ductal stem cells (ndscs), which are adult stem cells having an ability to differentiate into har-nds-derived neural cells, and hematopoietic stem cells having an ability to differentiate into blood ...
NEW Methods for treating neurological disorders
Alzheon ,inc.
June 22, 2017 - N°20170172952

Disclosed herein are methods and compositions for treating, ameliorating, and/or preventing alzheimer's disease in apoe4-postitive patients using particular compounds and compositions thereof.
NEW Pharmaceutical composition containing pregabalin with improved stability and method for preparing same
Yungjin Pharm. Co., Ltd.
June 22, 2017 - N°20170172929

Provided are a sustained-release composition including pregabalin and a pharmaceutically acceptable salt thereof using a gastroretentive drug delivery system (grdds), an oral sustained-release formulation using the composition, and a preparation method thereof. In a sustained-release composition according to the present invention and a formulation including the same, a coating compartment including a sugar or a derivative thereof and a plasticizer ...
NEW Neurological Patent Pack
Download 364+ patent application PDFs
Neurological Patent Applications
Download 364+ Neurological-related PDFs
For professional research & prior art discovery
inventor
  • 364+ full patent PDF documents of Neurological-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Method, system and apparatus for fall detection
University Health Network
June 22, 2017 - N°20170172465

Methods, systems, and apparatuses are provided for detecting fall events of a person. Fall events are falls that are likely to occur, are occurring, or have occurred. Fall detectors and fall detector systems detect fall events of the person. Data relating to the person are received from sensors and analyzed to perform fall detection. Data relating to the person includes ...
Quinuclidine compounds for modulating alpha7-nicotinic acetylcholine receptor activity
Alpharmagen, Llc
June 15, 2017 - N°20170166561

Provided are substituted quinuclidine compounds, pharmaceutical compositions comprising such compounds, and methods of modulating α7 nicotinic acetylcholine receptors and treating neurological disorders using such compounds.
Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions
Takeda Pharmaceutical Company Limited
June 15, 2017 - N°20170166553

The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof, in which r1, r2, r3, r4 and r5 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Apparatus and method for electromagnetic treatment of neurological injury or condition caused by a stroke
Takeda Pharmaceutical Company Limited
June 15, 2017 - N°20170165496

Described herein are methods of treating neurological injury and conditions, in particular symptoms and complications arising from or caused by a stroke. These treatment methods can include the steps of generating a pulsed electromagnetic field from a pulsed electromagnetic field source and applying the pulsed electromagnetic field in proximity to a target region.
Sustained release aminopyridine composition
Alkermes Pharma Ireland Limited
June 15, 2017 - N°20170165245

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 ...
Advanced play environment for screening and early diagnosis of infant developmental delays and neurological impairments
The Trustees Of The University Of Pennsylvania
June 15, 2017 - N°20170164900

The presently disclosed subject matter relates to a play environment for children and infants for detecting motor delays or impairments, evaluating neurological development, and for diagnosing developmental disorders, and methods and systems of using the same.
Imidazopyridine derivatives as modulators of tnf activity
Ucb Biopharma Sprl
June 08, 2017 - N°20170158688

A series of substituted 1h imidazo[4,5-c]pyridine derivatives of formula (i), being potent modulators of human tnfa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Neurological Patent Pack
Download 364+ patent application PDFs
Neurological Patent Applications
Download 364+ Neurological-related PDFs
For professional research & prior art discovery
inventor
  • 364+ full patent PDF documents of Neurological-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Systems and methods for the development of therapy paradigms for neurological treatments
Boston Scientific Neuromodulation Corporation
June 08, 2017 - N°20170157404

Methods, devices and systems for developing new therapy options for patient suffering from neurological disorders. An example may include the use of a therapy patterning system that allows significant freedom to program therapy patterns using arbitrary shapes and functions. For such patterning to be implemented, a physician may identify a condition needing new and/or alternative therapy options, link the ...
Concentrated felbamate formulations for parenteral administration
Perosphere Inc.
June 08, 2017 - N°20170157083

Formulations of a neuroprotective agent for parenteral administration are described herein. The formulation is in the form of a concentrated (supersaturated) solution or a concentrated suspension of microparticles. The suspension medium or the solution solvent carrier may also contain dissolved neuroprotective agent. For the supersaturated solutions, the agent is dissolved a high concentrations of at least about 1% by weight, 5% by ...
Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
Neuroderm, Ltd.
June 08, 2017 - N°20170157077

Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the ...
Collecting gait information for evaluation and control of therapy
Medtronic, Inc.
June 08, 2017 - N°20170156663

A medical device delivers a therapy to a patient. The medical device or another device may periodically determine an activity level or gait parameter of the patient, and associate each determined level or parameter with a current therapy parameter set. A value of at least one activity metric is determined for each of a plurality of therapy parameter sets based ...
Method
Oxford University Innovation Limited
June 01, 2017 - N°20170153234

The invention relates to methods of determining whether or not an individual has or is likely to develop a neurological disease and related methods and kits.
Pde10 inhibitors and related compositions and methods
Omeros Corporation
June 01, 2017 - N°20170152238

Compounds that inhibit pde10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as parkinson's disease, huntington's disease, alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, bell's palsy, cerebral palsy, sleep disorders, pain, tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive ...
Brain stimulation system including multiple stimulation modes
Functional Neuromodulation Inc.
June 01, 2017 - N°20170151436

A system for treating a patient comprises a stimulator for stimulating brain tissue, a controller for setting stimulation parameters and a diagnostic tool for measuring patient parameters and producing diagnostic data. The stimulation parameters comprise test stimulation parameters and treatment stimulation parameters. The stimulator delivers test stimulation energy to the brain tissue based on at least one test stimulation parameter ...
Pharmaceutical composition combining an anticonvulsant and a derivate of nicotinic acid
Functional Neuromodulation Inc.
June 01, 2017 - N°20170151223

The clg combination is safe, because it shows no adverse effects on motor activity or alterations in neurological parameters nor damage to the liver or kidney.
Loading